NP001

An experimental drug targets the immune system in ALS, switching cells from 'attack' to 'protective' mode

Posted on Tuesday, June 15, 2010 - 13:37, By: Amy Madsen
Neuraltus Pharmaceuticals of Palo Alto, Calif., is developing a small molecule whose target is regulation of immune system cells believed to contribute to neuroinflammation and disease progression in ALS (amyotrophic lateral sclerosis, or Lou Gehrig's disease). About ALS mechanisms  

Advertisements

myMuscleTeam